Company can in-license NOV originated projects
Company can in-license NOV’s oncology projects
NOV co-develops NOV originated projects with overseas company
NOV develops/co-develops NOV originated projects (pre-clinical or clinical) with overseas company through drug development infrastructure, extensive networks, expert’s know-how, as well as development funds.
NOV partners up with a Korean Company to develop in-licensing overseas projects
NOV can join a domestic company to develop in-licensing oncology projects from global bio/pharmaceutical companies as a co-development partner. The domestic company must have commercialization rights for at least Asian markets including the Korean territory.